VDAC2: A Potential Drug Target for Various Diseases (G7417)

Target Name: VDAC2

NCBI ID: G7417

VDAC2

VDAC2: A Potential Drug Target for Various Diseases

VDAC2 (POR), a protein that belongs to the family of phospholipase D (PLD) enzymes, has been identified as a potential drug target or biomarker for various diseases, including heart disease, diabetes, and cancer. Its unique function in the body and its involvement in multiple cellular processes have made it an attractive target for researchers to explore.

PLD enzymes are a family of transmembrane proteins that play a crucial role in the phosphatidyl choline (PC) synthesis pathway. This pathway is involved in the formation of essential cell components, including cell membrane, cell organelle membrane, and various organelles. PLD enzymes are involved in the breaking down of phosphatidylcholine (PC) to generate phosphorylcholine (PC) and phospholipase A2 (PLA2), which are vital for the formation of cell membranes.

VDAC2, as a member of the PLD enzyme family, is involved in the regulation of PC synthesis and breakdown. It has been shown to play a critical role in the development and progression of various diseases, including heart disease, diabetes, and cancer.

One of the key functions of VDAC2 is its role in the regulation of lipid metabolism. It is involved in the synthesis and breakdown of various lipids, including PC, which are essential for the formation of cell membranes. The levels of PC in the cell membrane are regulated by VDAC2, and changes in its activity can have a significant impact on the membrane properties and the function of the cell.

VDAC2 is also involved in the regulation of cellular signaling pathways. It has been shown to play a role in the signaling pathways that regulate cell growth, differentiation, and inflammation. Its activity has been shown to be regulated by various signaling pathways, including TGF- 尾, PI3K, and NF-kappa-B.

In addition to its role in cellular signaling, VDAC2 is also involved in the regulation of inflammation. It has been shown to play a critical role in the regulation of inflammation and inflammation-related diseases. Its activity has been shown to be regulated by various signaling pathways, including TGF-β, NF-kappa-B, and IL-6.

VDAC2 has also been shown to be involved in the regulation of cellular transport processes. It plays a role in the regulation of the endosomal system, which is responsible for the delivery of cellular and viral particles to the cytosol. Its activity has been shown to be Regulated by various signaling pathways, including TGF-β and NF-kappa-B.

In conclusion, VDAC2 is a protein that has been shown to play a critical role in various cellular processes that are involved in the development and progression of diseases. Its unique function in the regulation of PC synthesis and breakdown, as well as its involvement in cellular Signaling pathways, inflammation, and cellular transport processes make it an attractive target for drug development. Further research is needed to fully understand the role of VDAC2 in the development and progression of diseases, as well as its potential as a drug or biomarker.

Protein Name: Voltage Dependent Anion Channel 2

Functions: Forms a channel through the mitochondrial outer membrane that allows diffusion of small hydrophilic molecules (By similarity). The channel adopts an open conformation at low or zero membrane potential and a closed conformation at potentials above 30-40 mV (By similarity). The open state has a weak anion selectivity whereas the closed state is cation-selective (By similarity). Binds various lipids, including the sphingolipid ceramide, the phospholipid phosphatidylcholine, and the sterol cholesterol (PubMed:31015432). Binding of ceramide promotes the mitochondrial outer membrane permeabilization (MOMP) apoptotic pathway (PubMed:31015432)

The "VDAC2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about VDAC2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets